FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 2243 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy and Descriptive Safety Assessment of Programmed Cell Death Protein-(Ligand) 1 Inhibitors Plus Chemotherapy as First-Line Treatment for Gastric and Gastroesophageal Junction Cancer in Asian and Non-Asian Patients: A Meta-Analysis. PMID 42109272 · Gastro Hep Adv · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy. PMID 42079658 · Front Immunol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer. PMID 42065071 · Oncol Res · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Meta-Analysis of All Randomized Clinical Trials with Subgroup Analysis by Patient Profile. PMID 42065038 · Oncol Res · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| KRASG12C inhibitors versus chemotherapy alone for KRASG12C-mutated non-small cell lung cancer: a pooled analysis of CodeBreaK 200 and KRYSTAL-12 trials. PMID 42063697 · Front Oncol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| CALGB 140503 and the shift to sublobar resection for small, peripheral, node-negative NSCLC: historical context, secondary analyses, and next steps. PMID 42038383 · Front Oncol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| De-escalation of head-and-neck cancer radiotherapy: balancing cure and side effects. PMID 42038372 · Front Oncol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Evolving therapeutic pipeline for tumor-infiltrating lymphocytes in metastatic melanoma - a review. PMID 41958653 · Front Immunol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for locally advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized phase III trials. PMID 41924604 · Front Oncol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Constrained Hierarchical Bayesian Model Considering Latent Biomarker Subgroups for Time-To-Event Endpoints in Randomized Phase II Trials. PMID 41905407 · Pharm Stat · 2026 The record is a statistical methodology paper proposing a model for future trials, not an original report of a completed trial's results. It does not contain a drug intervention or present trial efficacy data. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027). PMID 41886441 · PLoS One · 2026 方案论文未报告临床试验结果。 |
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial. PMID 41883618 · Ther Adv Hematol · 2026 This is a protocol for an ongoing randomized, phase IIb trial. While it meets criteria for oncology, human, randomized, and drug intervention, it does not report any results. Furthermore, the primary endpoint (proportion with >=35% spleen volume reduction at week 24) is a categorical response, not a time-to-event endpoint. No time-to-event data or analysis (e.g., OS, PFS, DFS, Kaplan-Meier, HR) is presented. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant chemoradiotherapy with or without PD-1 inhibitors in MMR-proficient non-metastatic rectal cancer: a meta-analysis of randomized controlled trials. PMID 41853263 · Front Immunol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Sex-based heterogeneity in response to first-line immunotherapy plus chemotherapy in advanced esophageal squamous-cell carcinoma: a meta-analysis. PMID 41836421 · Front Immunol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Advances in Systemic Therapy for Unresectable Hepatocellular Carcinoma: Commentary on The Impact of the STRIDE Regimen in HIMALAYA Trial. PMID 41799527 · Oncol Res · 2026 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Radiotherapy plus immune checkpoint inhibitors versus immune checkpoint inhibitors alone for non-small cell lung cancer with bone metastases: a systematic review and meta-analysis of comparative cohort studies. PMID 41798915 · Front Immunol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison. PMID 41788456 · Biologics · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. PMID 41737914 · BMJ Oncol · 2026 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 1 Figure · 3 Panel · risk visible |
| Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer. PMID 41737486 · Front Oncol · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immunotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized clinical trials. PMID 41669379 · Ther Adv Med Oncol · 2026 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Study protocol for a multicenter phase II prospective externally controlled non-inferiority trial of hypofractionated re-irradiation in patients with recurrent high-grade glioma (RISinG). PMID 41662245 · PLoS One · 2026 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Determinants of publication likelihood and timeliness for clinical studies. PMID 41536814 · J Clin Transl Sci · 2026 The record is a meta-analytical study of factors predicting publication timeliness for clinical trials, not an original report of a Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary time-to-event endpoint. It lacks the specific trial results required. |
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant treatment in resectable pancreatic cancer: Why is upfront surgery so hard to be beaten? PMID 41024839 · World J Clin Oncol · 2025-Sep-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Immune Checkpoint Inhibitors Beyond Progression in Various Solid Tumors: A Systematic Review and Pooled Analysis. PMID 41010884 · J Clin Med · 2025-Sep-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Flap sparing in postoperative radiotherapy versus standard flap-agnostic radiotherapy of oral cavity cancers (OPTIFLAP): protocol for a de-escalation, randomised, non-inferiority, phase III trial. PMID 40953868 · BMJ Open · 2025-Sep-14 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Choosing the best first-line therapy for extensive-stage small-cell lung cancer: anti-PD-1 or anti-PD-L1 inhibitors? PMID 40922293 · Medicine (Baltimore) · 2025-Sep-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials. PMID 40838872 · Oncologist · 2025-Sep-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Expected vs observed effect sizes for survival endpoints in phase 3 oncology trials. PMID 40600894 · J Natl Cancer Inst · 2025-Sep-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 study. PMID 41647991 · ESMO Gastrointest Oncol · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations. PMID 41647988 · ESMO Gastrointest Oncol · 2025-Sep 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer. PMID 40907528 · Lancet Oncol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study. PMID 40896460 · EClinicalMedicine · 2025-Sep 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. PMID 40763418 · Gynecol Oncol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A systematic review of the efficacy of cancer vaccines in advanced breast cancer. PMID 40762664 · Breast Cancer · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Duration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial. PMID 40752730 · Actas Urol Esp (Engl Ed) · 2025-Sep The record is a protocol for a Phase III randomized trial with a drug intervention and a time-to-event endpoint, but it does not report formal results. It is excluded as a protocol without results. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prostate radiotherapy in patients with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis of randomised controlled trials. PMID 40687731 · Clin Transl Radiat Oncol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of systemic therapy for advanced hepatocellular carcinoma based on etiology: A systematic review and network meta-analysis of randomized phase III trials. PMID 40645358 · Crit Rev Oncol Hematol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. PMID 40644648 · J Clin Oncol · 2025-Sep 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 1 Figure · 2 Panel · risk visible |
| Cardiac and vascular toxicity of amivantamab in non-small cell lung cancer (NSCLC): A systematic review. PMID 40617324 · Crit Rev Oncol Hematol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors. PMID 40545422 · Clin Lung Cancer · 2025-Sep 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data. PMID 40531349 · Expert Rev Anticancer Ther · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for TKIs-resistant, EGFR-mutant, advanced non-small-cell lung cancer: a phase 3 RCTs based meta-analysis. PMID 40531080 · Expert Rev Anticancer Ther · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1-Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. PMID 40494752 · Clin Lung Cancer · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy, safety and cost-effectiveness of chemo-immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: an updated systematic review and cost-effectiveness analysis. PMID 41234878 · Transl Cancer Res · 2025-Oct-31 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant systemic therapy for pleural mesothelioma patients: a systematic review. PMID 41234589 · Transl Lung Cancer Res · 2025-Oct-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Investigation of an integrated standardised pain assessment and management tool in addition to usual care versus usual care alone in oncology outpatient clinics for adults with pain: the CAPTURE cluster randomised pilot trial protocol. ISRCRN86926298. PMID 41168902 · Pilot Feasibility Stud · 2025-Oct-30 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 Years. PMID 41228275 · Cancers (Basel) · 2025-Oct-29 The record describes a pre-planned subgroup analysis of a Phase III randomized trial, not the primary result report for the entire trial population. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). PMID 41152774 · BMC Cancer · 2025-Oct-28 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Emerging Applications of Stereotactic Ablative Radiotherapy in Oligometastatic Colorectal Cancer. PMID 41226343 · Int J Mol Sci · 2025-Oct-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparison of the safety and efficacy of moderately hypofractionated and conventionally fractionated radiotherapy for localized prostate cancer: evidence from 9074 men in 13 randomized clinical trials. PMID 41131510 · BMC Cancer · 2025-Oct-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |